ARVN ARVINAS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1655759 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-11.8%
TTM net income YoY83.8%
TTM EPS YoY90.1%
Revenue 3-yr CAGR18.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-12.1%
Net margin-3.5%
FCF margin-58.0%
EBITDA margin-11.2%
Returns
ROE-1.8%
ROA-1.3%
ROIC (approx.)-5.9%
Asset turnover0.38x
Leverage & solvency
Liabilities / assets15.4%
Debt / equity0.00x
Current ratio8.39x
Interest coverage—
Cash quality & payout
Operating cash flow / net income16.66x
Accruals ratio20.5%
Payout ratio—
Capex / revenue0.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $262.60M | $263.40M |
| R&D expense | $285.20M | $348.20M |
| SG&A expense | $95.90M | $165.40M |
| Operating income | -$118.50M | -$250.20M |
| Interest expense | — | $0 |
| Pretax income | -$80.50M | -$198.30M |
| Income tax | $300,000 | $600,000 |
| Net income | -$80.80M | -$198.90M |
| EBITDA | -$115.50M | -$245.60M |
| EPS (basic) | -1.14 | -2.77 |
| EPS (diluted) | -1.14 | -2.77 |
| Weighted avg. shares (diluted) | 70.90M | 71.90M |
| Balance sheet | ||
| Cash & equivalents | $142.90M | $100.50M |
| Short-term investments | $542.50M | $938.90M |
| Receivables | $1.00M | $5.70M |
| Current assets | $700.70M | $1.07B |
| PP&E, net | $5.20M | $7.00M |
| Total assets | $717.90M | $1.09B |
| Current liabilities | $142.50M | $229.80M |
| Short-term debt | $200,000 | $200,000 |
| Long-term debt | $400,000 | $600,000 |
| Total debt | $600,000 | $800,000 |
| Total liabilities | $284.00M | $529.70M |
| Shareholders' equity | $433.90M | $561.70M |
| Net debt | -$142.30M | -$99.70M |
| Shares outstanding | 63.50M | 68.80M |
| Cash flow statement | ||
| Operating cash flow | -$273.80M | -$259.30M |
| Capital expenditure | $1.90M | $1.80M |
| Free cash flow | -$275.70M | -$261.10M |
| Investing cash flow | $407.60M | $34.70M |
| Financing cash flow | -$91.40M | $7.90M |
| Depreciation & amortization | $3.00M | $4.60M |
| Stock-based compensation | $44.00M | $88.20M |
| Share buybacks | $91.90M | $0 |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.